Alcon Inc. ALC.SW
Composite 47/100; the shares have moved about 29% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 34/100 — a moderate mark against it.
Balance-sheet strength ranks 64/100 — a moderate point in its favour. Growth ranks 56/100 — a slight point in its favour.
Momentum ranks 34/100 — a moderate mark against it. Quality ranks 38/100 — a slight mark against it. Income ranks 40/100 — a slight mark against it.
What the company does Alcon Inc. (ALC.SW) is a global leader in eye care, operating through Surgical and Vision Care segments. It provides cataract equipment, intraocular lenses, surgical consumables, and vitreoretinal products, including advanced platforms like LenSx and NGENUITY.
Key financials Alcon’s profitability metrics are mixed: ROE 4%, ROA 3%, and net margin 8%. Revenue grew 9% YoY, but EPS fell -45%. Margins show gross at 56% and operating at 12%, with a strong current ratio of 2.20 and debt/equity of 0.24.
Stock health Momentum is weak: -22% from its 52-week high, with 12-month returns at -22%. RSI(14) stands at 61, indicating slight upward pressure but no strong trend. Sideravia scores the stock Weak Quality (39) and Weak Momentum (31).
Price vs fair value The stock trades at a **PREMIUM of 23.50%** to our fair-value estimate of 43.72 and a **discount of 33.27%** to the 12-month target of 76.15. - Fair-value premium reflects high P/E (41x) vs forward 20x and EV/EBITDA 14.5x (Valuation 48). - Weak momentum (31) and RSI 61 suggest limited near-term upside. - Analysts cite surgical demand risks tied to medical customer trends (Zacks, 2026-07-27). - Options activity hints at uncertainty (Zacks, 2026-07-30).
Looking forward Forward P/E of 20x implies growth expectations, but net margin compression (-45% EPS) and weak momentum (31) temper optimism. Debt levels are manageable, but ROE at 4% lags sector peers. Watch surgical procedure trends and IOL adoption for catalysts.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.